Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Current Leases data on file, last reported at $5.5 million in Q4 2025.

• Current Leases for Q4 2025 came in at $5.5 million, up 239.89% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.5 million (up 239.89% YoY), and the FY2025 annual result was $5.5 million, up 258.86% from the prior year.
• Current Leases advanced to $5.5 million in Q4 2025 per TLX's latest filing, from $1.6 million in the prior quarter.
• Over five years, Current Leases peaked at $5.5 million in Q4 2025 and troughed at $387339.3 in Q4 2023.
• A 3-year average of $2.5 million and a median of $1.6 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2024 and 2025: Current Leases jumped 321.41% in 2024, then jumped 239.89% in 2025.
• A 3-year view of Current Leases shows it stood at $387339.3 in 2023, then jumped by 321.41% to $1.6 million in 2024, then jumped by 239.89% to $5.5 million in 2025.
• Business Quant data shows TLX's Current Leases at $5.5 million in Q4 2025, $1.6 million in Q4 2024, and $387339.3 in Q4 2023.